Katalyze AI announced $10.5 million USD ($14.9 million CAD) in seed funding on Monday to deploy its workflow software across large pharmaceutical firms.
The news: Katalyze is building an agentic operating system for pharma firms. The startup’s platform allows pharma workers to build teams of AI agents to tackle engineering, scientific, and manufacturing tasks. With its all-equity seed round, which closed this spring and was led by Bonfire Ventures, Katalyze aims to grow its 40-person team, expand its agent catalogue, and scale its deployments across major pharma firms. At the moment, it is already used by five of the world’s 20 biggest, including Sanofi.
From the source: “It takes eight to twelve years and more than two billion dollars to bring a drug to market,” Katalyze co-founder and CEO Reza Farahani told BetaKit over email. “We want to cut that in half by 2030, and we’re starting where the industry loses the most time: the operational and manufacturing arc.”
Following the thread: While Katalyze is domiciled in the US, it is dual-headquartered in both Toronto and San Francisco. The majority of Katalyze’s founding team is either located in Toronto or has ties to Toronto, including Canadian co-founder Farahani and COO Shreyas Becker.
Farahani is a University of Waterloo grad who previously co-founded and sold Toronto human resources software startup WFHomie, while Becker studied at the University of British Columbia, spent time at Neo Financial, and was head of AI and data products for manufacturing and supply at Sanofi in Toronto. Montréal’s Inovia Capital and Toronto-based Ripple Ventures also sit on Katalyze’s cap table.
Final thought: At a time when Canada’s most promising founders are increasingly choosing to build in the US, Farahani said that splitting Katalyze’s presence between San Francisco and Toronto offers a strong talent mix, while providing geographic proximity to Silicon Valley venture capitalists and Toronto’s pharma industry.
Feature image courtesy Katalyze AI.